Sauvage Philippe 4

What Happened Philippe Sauvage, Chief Financial Officer of Nuvation Bio (NUVB), exercised stock-option rights on July 15, 2026 to acquire 40,000 shares of common stock (transaction code M). The filing shows 39,999 shares exercised at an exercise price of $2.17 (total $86,798) and 1 share exercised at $1.97 (≈ $2), for a combined cash outlay of about $86,800. The corresponding derivative entries were marked disposed at $0.00, indicating the options were converted into common shares.

Key Details

• Transaction date: July 15, 2026; Form 4 filed July 17, 2026 (filed within two business days — appears timely).
• Prices and amounts: 39,999 shares @ $2.17 = $86,798; 1 share @ $1.97 ≈ $2; total ≈ $86,800.
• Transaction type: M = exercise/conversion of derivative (options). The options were converted into shares (no sale of shares reported).
• Shares owned after transaction: Not specified in the excerpt provided.
• Footnotes: F1 notes 1,458 shares purchased via the company ESPP on May 19, 2026. F2 and F3 describe typical multi-year vesting schedules for the options (25% after 1 year, then monthly over 36 months), subject to continued service.

Context This was an options exercise (insider acquiring shares) rather than an open-market sale; the filing does not report an immediate sale of the acquired shares (not a cashless exercise). Exercises are common for employees to convert vested option rights into stock and may reflect routine option management rather than a market view. All information above is factual from the Form 4 filing excerpt and does not speculate on Sauvage’s motives.